Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply or raise costs for its own citizens – officials told U.S. authorities – in a new setback to the Trump administration’s efforts to tackle high drug prices, according to documents obtained by Reuters.
While Boston tends to get the lion’s share of recognition as the premier biopharma hub on the East Coast of the United States, other cities and states are looking to make their names known as a strong location for the industry. New Jersey, New York and New Hampshire have gone to great lengths to distinguish themselves, but so too has smaller Rhode Island.
New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.
Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.
The FDA issued warning letters to two companies for illegally selling unapproved drug products that contain the herbal extract kratom.
The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.
Contract research organization Catalent plans to buy Bristol-Myers Squibb’s manufacturing and packaging factory in Anagni, Italy, used to manufacture oral solid, biologics and sterile products.
Sanofi said a reorganization of the company’s research and development operation in Germany and France would result in 466 job cuts in the two countries.
A Canadian advisory council studying prescription drug coverage said the federal government should create a universal, single-payer public pharmacare system, and warned that the current framework requires significant reforms.